Posts by: Iqra Mumal

News

A rat model genetically engineered to express high levels of two genes can help researchers learn more about the disease mechanisms that lead to Alzheimer’s disease, a new study ... Read more

March 21, 2018March 21, 2018

Bryostatin Improves Cognition in Patients with Advanced Alzheimer’s, Analysis Finds

News

Bryostatin, Neurotrope Bioscience’s investigational therapy, was associated with improved cognition in advanced Alzheimer’s disease patients in post-hoc (after-the-fact) analysis of a Phase 2 trial. Results from this study were presented ... Read more

January 31, 2018

Poor Results Prompt Takeda and Zinfandel to End Phase 3 Alzheimer’s Therapy Trial Early

News

Takeda Pharmaceutical Company and Zinfandel Pharmaceuticals have brought an early end to a Phase 3 clinical trial after their Alzheimer’s therapy pioglitazone failed to prevent the development of mild cognitive impairment. The ... Read more

January 8, 2018January 8, 2018

Diabetes Therapy Could Be Used to Treat Alzheimer’s, Study Reports

News

An approved treatment for diabetes may help people with Alzheimer’s, a study reports. The research, “Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model ... Read more

January 5, 2018January 5, 2018

First Participants Dosed in a Phase 1 Clinical Trial of COR388

News

The pharmaceutical company Cortexyme announced that the first group of participants has been dosed in the Phase 1 clinical trial of its lead compound, COR388, for the treatment of Alzheimer’s ... Read more

December 11, 2017

Study Links Lower Alzheimer’s Death Rates to Lithium in Drinking Water

News

Trace levels of lithium in drinking water reduce Alzheimer’s death rates in addition to two risk factors for the disease — obesity and Type 2 diabetes, according to a ... Read more

December 5, 2017December 5, 2017

Early Alzheimer’s Study Finds Nanoparticle May Help Deliver Treatments Directly to Brain

News

Researchers found that the combination of titanate, a nanoparticle that can penetrate the brain-blood barrier, and cerebrolysin, used in some parts of the world to treat problems with cognition, ... Read more

November 22, 2017November 22, 2017

Psychotic Alzheimer’s Patients More Likely To Be Misdiagnosed, Study Finds

News

Doctors tend to miss Alzheimer’s diagnosis in psychotic patients more likely than than non-psychotic ones, according to new research by Canada’s University of Toronto. The study, “Determining the impact ... Read more

November 14, 2017

Potential Therapy, CT1812, Seen as Safe and Able to Target Disease Markers, Cognition Reports

News

Cognition Therapeutics’ lead drug candidate for mild-to-moderate Alzheimer’s disease (AD), CT1812, was shown to be well-tolerated and to lower brain levels of proteins involved in the disease, the company ... Read more

November 9, 2017December 7, 2017

Biogen, Citing New Phase 1 Data, Says Aducanumab Reduces Amyloid Plaques in Alzheimer’s

News

Aducanamab helps reduce amyloid plaques in Alzheimer’s patients who receive a gradually increasing dose of the therapy, its developer, Biogen, reports, citing results from the long-term extension of its ... Read more

Posts by: Iqra Mumal

Iqra Mumal

New Genetically Engineered Rat Model Can Aid Alzheimer’s Research, Study Says

Bryostatin Improves Cognition in Patients with Advanced Alzheimer’s, Analysis Finds

Poor Results Prompt Takeda and Zinfandel to End Phase 3 Alzheimer’s Therapy Trial Early

Diabetes Therapy Could Be Used to Treat Alzheimer’s, Study Reports

First Participants Dosed in a Phase 1 Clinical Trial of COR388

Study Links Lower Alzheimer’s Death Rates to Lithium in Drinking Water

Early Alzheimer’s Study Finds Nanoparticle May Help Deliver Treatments Directly to Brain

Psychotic Alzheimer’s Patients More Likely To Be Misdiagnosed, Study Finds

Potential Therapy, CT1812, Seen as Safe and Able to Target Disease Markers, Cognition Reports

Biogen, Citing New Phase 1 Data, Says Aducanumab Reduces Amyloid Plaques in Alzheimer’s

Pin It on Pinterest